SG Americas Securities LLC Makes New Investment in Indivior PLC $INDV

SG Americas Securities LLC acquired a new position in Indivior PLC (NASDAQ:INDV) in the second quarter, HoldingsChannel.com reports. The institutional investor acquired 36,206 shares of the company’s stock, valued at approximately $534,000.

Other large investors have also recently made changes to their positions in the company. Amalgamated Bank purchased a new position in Indivior during the second quarter valued at $61,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in Indivior by 16.0% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,820 shares of the company’s stock worth $71,000 after buying an additional 666 shares during the last quarter. CTC Alternative Strategies Ltd. bought a new position in shares of Indivior in the first quarter worth approximately $96,000. Y Intercept Hong Kong Ltd purchased a new stake in shares of Indivior during the first quarter valued at approximately $207,000. Finally, State of New Jersey Common Pension Fund D purchased a new position in Indivior in the 2nd quarter worth approximately $262,000. 60.33% of the stock is currently owned by hedge funds and other institutional investors.

Indivior Price Performance

Shares of INDV opened at $33.48 on Thursday. The firm has a market capitalization of $4.62 billion, a P/E ratio of 54.00 and a beta of 0.68. Indivior PLC has a one year low of $7.62 and a one year high of $33.64. The business has a fifty day moving average of $26.98 and a 200 day moving average of $20.85.

Indivior (NASDAQ:INDV) last posted its earnings results on Thursday, October 30th. The company reported $0.72 earnings per share for the quarter, beating analysts’ consensus estimates of $0.38 by $0.34. The company had revenue of $314.00 million for the quarter, compared to the consensus estimate of $257.66 million. Indivior had a negative return on equity of 86.28% and a net margin of 6.65%. Indivior has set its FY 2025 guidance at EPS. Analysts expect that Indivior PLC will post 1.22 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have commented on the company. Northland Securities set a $40.00 target price on Indivior in a report on Friday, October 31st. Piper Sandler reaffirmed an “overweight” rating and set a $41.00 price objective (up from $27.00) on shares of Indivior in a research report on Friday, October 31st. HC Wainwright lifted their price objective on Indivior from $28.00 to $35.00 and gave the stock a “buy” rating in a report on Thursday, October 30th. Craig Hallum reissued a “buy” rating and issued a $41.00 target price on shares of Indivior in a research report on Friday, October 31st. Finally, Zacks Research raised shares of Indivior from a “hold” rating to a “strong-buy” rating in a report on Monday, November 3rd. Two research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, Indivior has an average rating of “Buy” and a consensus target price of $32.17.

Indivior Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.